Current misconceptions in diagnosis and management of iron deficiency by Muñoz, Manuel et al.
422
Blood Transfus 2017; 15: 422-37  DOI 10.2450/2017.0113-17
© SIMTI Servizi Srl
Rਅਖਉਅਗ
Current misconceptions in diagnosis and management of iron deficiency
Manuel Muñoz1, Susana Gómez-Ramírez2, Martin Besser3, José Pavía4, Fernando Gomollón5,
Giancarlo M. Liumbruno6, Sunil Bhandari7, Mercé Cladellas8, Aryeh Shander9, Michael Auerbach10
1Perioperative Transfusion Medicine, Department of Surgical Sciences, Biochemistry and Immunology, School of 
Medicine, University of Málaga, Málaga, Spain; 2Department of Internal Medicine, University Hospital "Virgen 
de la Victoria", Málaga, Spain; 3Department of Haematology, Cambridge University Hospitals NHS Foundation 
Trust, Cambridge, United Kingdom; 4Department of Pharmacology, School of Medicine, University of Málaga, 
Málaga, Spain; 5Department of Gastroenterology, University Hospital "Lozano Blesa", IIS Aragón, CIBERehd, 
Zaragoza, Spain; 6Italian National Blood Centre, National Institute of Health, Rome, Italy; 7Metabolic Research 
Unit, Hull and East Yorkshire Hospitals NHS Trust; Hull York Medical School, Kingston upon Hull, United 
Kingdom; 8Biomedical Research Institute, University Hospital Mar-Esperança, Barcelona, Spain; 9Department 
of Anesthesiology, Critical Care Medicine, Pain Management and Hyperbaric Medicine, TeamHealth Research 
Institute, Englewood Hospital and Medical Centre, Englewood, NJ, United States of America; 10Georgetown 
University School of Medicine, Washington, DC, United States of America
Abstract
The prevention and treatment of iron deficiency is 
a major public health goal. Challenges in the treatment 
of iron deficiency include finding and addressing 
the underlying cause and the selection of an iron 
replacement product which meets the needs of the 
patient. However, there are a number of non-evidence-
based misconceptions regarding the diagnosis and 
management of iron deficiency, with or without anaemia, 
as well as inconsistency of terminology and lack of 
clear guidance on clinical pathways. In particular, the 
pathogenesis of iron deficiency is still frequently not 
addressed and iron not replaced, with indiscriminate 
red cell transfusion used as a default therapy. In our 
experience, this imprudent practice continues to be 
endorsed by non-evidence-based misconceptions. The 
intent of the authors is to provide a consensus that 
effectively challenges these misconceptions, and to 
highlight evidence-based alternatives for appropriate 
management (referred to as key points). We believe that 
this approach to the management of iron deficiency may 
be beneficial for both patients and healthcare systems. 
We stress that this paper solely presents the Authors' 
independent opinions. No pharmaceutical company 
funded or influenced the conception, development or 
writing of the manuscript. 
Key words: iron deficiency, anaemia, oral iron, 
intravenous iron, misconceptions.
Introduction
Using World Health Organization (WHO) criteria for 
defining anaemia, data from 187 countries revealed a 
significant reduction in the prevalence of global anaemia 
from 40.2% in 1990 to 32.9% in 2010, with wide 
variations across regions1. Decreases in the prevalence 
of mild and moderate anaemia accounted for most of 
the reduction, while the prevalence of severe anaemia 
remained largely unchanged. Iron deficiency (ID) 
remains the most common cause of anaemia worldwide, 
accounting for about one half of all cases. Other common 
causes include infestations, congenital anaemias (e.g., 
haemoglobinopathies), and anaemia associated with 
chronic kidney disease (CKD), although, again, the 
proportion of cases resulting from specific causes varies 
widely across regions1.
The prevention and treatment of ID is a major 
public health goal, especially in women, children, and 
individuals in low-income countries. Challenges in 
the treatment of ID include finding and addressing the 
underlying cause and the selection of an iron replacement 
product which meets the needs of the patient2,3.
There are a number of non-evidence-based 
misconceptions regarding the diagnosis and management 
of ID, either with anaemia (IDA) or without anaemia 
(NAID), as well as inconsistency of terminology 
and lack of clear guidance on clinical pathways4,5. In 
particular, the pathogenesis of IDA is still frequently 
not addressed and iron not replaced, with indiscriminate 
red cell transfusion used as a default therapy. In our 
experience, this imprudent practice continues to be 
endorsed by non-evidence-based misconceptions. 
Methodology
Following the methodology used in previous 
publications5,6, the corresponding Author (MM) invited 
co-Authors to participate and drafted a preliminary list 
of misconceptions on the diagnosis and management 
of IDA and NAID (based on the current practice of 
the Authors, who are actively working in the field of 
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anaemia, both in Europe and the USA). The intent of 
the Authors was to provide a consensus that effectively 
challenges these misconceptions, and to highlight 
what we collectively consider should be appropriate 
management (referred to as key points). We stress that 
this paper solely contains the Authors' independent 
opinions. No pharmaceutical company funded or 
influenced the conception, development or writing of 
the manuscript.
Misconception #1 
Iron status can be easily evaluated and normal 
ferritin concentrations exclude iron deficiency
Appropriate assessment of iron status and 
definitions of ID are paramount when prescribing 
iron supplementation. In the early stages of ID, 
haematopoiesis is not affected. As iron stores diminish 
further, the red cells become microcytic (mean 
corpuscular volume <80 PL) and then hypochromic 
(mean corpuscular haemoglobin <28 pg). Greater red 
cell distribution width (RDW>15, anisocytosis) and 
thrombocytosis can be also observed on blood counts 
of patients with ID. The peripheral blood smear (slide) 
may show microcytosis, hypochromia, anisocytosis and 
poikilocytosis. Although often overlooked, a corrected 
reticulocyte count is necessary for the classification of 
anaemia. The reticulocyte production index (RPI) is 
calculated according to the formula: 
RPI= ([% reticulocytes]×[haematocrit/45])×0.5
(a RPI >2 is not compatible with IDA3).
Serum ferritin is the most frequently used laboratory 
test for evaluating iron stores. Although there may be 
some variability in normal ranges between laboratories, 
generally ferritin values between 30-300 ng/mL are 
regarded as normal2,7. A serum ferritin level <30 ng/mL 
is the most sensitive (92%) and specific (98%) cut-
off level for the identification of absolute ID, with or 
without anaemia8, but most clinical laboratories still 
use lower cut-off levels (<15-25 ng/mL)9. Thus, it is 
generally believed that serum ferritin values within the 
"normal range" exclude the presence of ID, but ferritin 
is an acute-phase reactant and its levels are profoundly 
affected by inflammation.
Transferrin saturation (TSAT) assesses the iron that is 
available for tissues and a low TSAT (<16-20%) further 
indicates insufficient iron supply to support normal 
erythropoiesis2,7. In the presence of inflammation (e.g., 
C-reactive protein >5 mg/L) and/or TSAT <20%, serum 
ferritin levels between 30 and 100 ng/mL suggest absolute 
ID, whereas ferritin levels >100 ng/mL argue against 
concurrent ID and usually indicate iron sequestration, 
as seen in anaemia of chronic inflammation 2,6,7.
Other tests, such as increased hypochromic red cells 
(HYPO >5%, Advia; Siemens Healthineers, Erlangen, 
Germany), low haemoglobin density (LHD >4%; 
Beckman-Coulter, Brea, California, CA, USA) and low 
reticulocyte haemoglobin content (CHr <29 pg, Advia, 
Siemens; Ret-HE <25 pg, Sysmex Corporation-Global, 
Kobe, Japan), are the best-established variables for the 
identification of absolute ID in this setting, which if 
present should be treated with iron supplementation6,7,10-13. 
Red blood cell size factor (RSF, Beckman-Coulter) is a 
parameter derived from the square root of the product 
of the mean corpuscular volume of erythrocytes and 
reticulocytes. RSF shows good correlation with CHr, 
with slightly better sensitivity and identical specificity 
for the detection of iron-restricted erythropoiesis; a RSF 
value <88% denotes ID14. All these tests have limitations 
in terms of sample stability or appropriate equipment 
availability. However, if available, they could potentially 
save money, time and confusion. The ratio of serum 
transferrin receptor to the log of ferritin (sTfr/log Ft >2; 
also called ferritin index), may have a role if red cell and 
reticulocyte parameters are unavailable11.
Several guidelines have issued recommendation for iron 
supplementation based on these diagnostic parameters. The 
European consensus on the diagnosis and management of 
iron deficiency and anaemia in inflammatory bowel disease 
(ECCO Guidelines), recommend iron supplementation, 
preferably intravenous (IV), for patients with ferritin levels 
<30 ng/mL or <100 ng/mL and TSAT <20%15. These 
definitions are also supported by guidelines on anaemia 
management in surgical patients16,17.
The Kidney Disease: Improving Global Outcomes 
(KDIGO) guidelines on anaemia management in CKD 
define absolute ID by ferritin <100 ng/mL and TSAT 
<20%. If an increase in haemoglobin concentration 
without starting treatment with an erythropoiesis-
stimulating agent (ESA) is desired, these guidelines 
suggest iron therapy (either IV or oral) if TSAT 
<25% and ferritin is <200 ng/mL in CKD patients not 
undergoing dialysis and <300 ng/mL in those undergoing 
dialysis18. For CKD patients on ESA treatment with 
TSAT ≤30% and ferritin ≤500 ng/mL, they also suggest 
iron therapy if an increase in haemoglobin concentration 
or a decrease in ESA dose is desired18.
Similarly, for patients with symptomatic chronic 
heart failure, the European Society of Cardiology 
guidelines define ID by serum ferritin <100 ng/mL, or 
ferritin between 100-299 ng/mL and TSAT <20%, and 
consider the administration of ferric carboxymaltose 
(FCM) in order to alleviate symptoms, and improve 
exercise capacity and quality of life19,20. 
In contrast, some guidelines for the management 
of cancer-related anaemia recommend administration 
of IV iron even at ferritin concentrations as high as 
500 or 800 ng/mL, if the TSAT is <40% in an ESA-
unresponsive patient21-23. 
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Key points
- Uncomplicated iron deficiency can be diagnosed by 
assessing standard iron parameters, such as serum 
ferritin and transferrin saturation.
- A low serum ferritin concentration (<30 ng/mL) is 
diagnostic for absolute iron deficiency, independently 
of any other parameter.
- In the setting of inflammation, serum ferritin levels 
between 30 and 100 ng/mL strongly suggest absolute 
iron deficiency.
- In the setting of inflammation with normal-to-
elevated ferritin levels (>100 ng/mL), assessments 
of haemoglobinisation of red cells (hypochromic red 
cells, low haemoglobin density) and reticulocytes 
(reticulocyte haemoglobin content, red blood cell 
size factor) are useful parameters for identifying 
the presence of iron-restricted erythropoiesis. The 
ferritin index may have a role if the above mentioned 
red cell and reticulocyte parameters are unavailable.
- In the setting of inflammation, ferritin levels within 
or even above the normal range do not exclude 
the presence of iron-restricted erythropoiesis and 
patients may still benefit from iron supplementation. 
However, at present no upper limit of ferritin can be 
universally proposed with certainty. When available, 
physicians should refer to specific guidelines18-23. 
Nonetheless, the level of evidence supporting the 
proposed ferritin cut-offs is generally low. 
Misconception #2 
Non-anaemic iron deficiency does not require any 
intervention
A normal haemoglobin level does not exclude ID. 
Individuals with normal body iron stores must lose 
a large portion of body iron before the haemoglobin 
falls below the laboratory definition of anaemia 
(generally, haemoglobin <13 g/dL for men, and 
<12 g/dL in non-pregnant women). In fact, the WHO 
recognises that "mild anaemia" (haemoglobin ≥11 g/dL 
- <12/13 g/dL) is a misnomer, as ID is already advanced 
by the time anaemia is detected, and has consequences 
even when no anaemia is clinically apparent9. 
Non-anaemic patients with reduced or absent iron 
stores (NAID) may have symptoms such as fatigue or 
reduced exercise tolerance (iron is required for optimal 
mitochondrial function essential for respiration and 
energy production)24. Most current guidelines do not 
recommend routine testing of iron parameters in the 
absence of anaemia. As a result NAID is invariably 
diagnosed in the laboratory25 when physicians are 
proactive. However, the benefit of oral or IV iron 
replacement for NAID-associated fatigue has been 
demonstrated in menstruating women, runners and 
blood donors26-34.
NAID is frequent in pregnancy and can adversely 
affect both the mother (increased risk of preterm 
delivery, Caesarean delivery and transfusion) and 
the neonate (increased risk of low APGAR score at 5 
minutes, intensive care admission, delayed growth and 
development and an increase in behavioural problems that 
persist up to 10 years after iron repletion)35,36. As total iron 
needs during pregnancy may exceed 1,000 mg, daily or 
alternate day iron supplementation (30-60 mg/day) during 
pregnancy may avoid preterm anaemia and minimise the 
probability of ID in the neonate37,38.
NAID is also prevalent among patients with gastro-
intestinal pathologies such as inflammatory bowel 
disease, gastric bypass, coeliac disease, Helicobacter 
pylori infection, and atrophic gastritis. In addition to 
the appropriate treatment for the underlying disease 
(e.g., gluten-free diet or antibiotics for Helicobacter 
pylori eradication), these patients may benefit from iron 
supplementation39,40.
In patients with cancer or inflammatory bowel disease, 
NAID may induce secondary thrombocytosis (platelet 
count ≥350,000/PL), which has been identified as an 
independent risk factor for thromboembolic events41,42. 
In experimental studies, ID alters megakaryopoiesis and 
platelet phenotype independently of thrombopoietin, 
through a mechanism mediated by increased expression 
of hypoxia-induced factor 2α43,44. The correction of 
ID lowers platelet counts and platelet activation in 
patients with CKD, cancer and inflammatory bowel 
disease-associated secondary thrombocytosis, and 
might contribute to reduce the risk of thromboembolic 
events45-48. Further investigation should clarify whether 
ID is a preventable cause of thrombosis, especially in 
the elderly.
In congestive heart failure, NAID was independently 
associated with compromised physical performance 
and quality of life, and an increase of all-cause and 
cardiovascular mortality; treatment of NAID with IV 
iron may improve functional status within four weeks, 
and these improvements are maintained after 24 weeks 
and 52 weeks20.
In observational studies of patients undergoing 
abdominal or cardiac surgery, pre-operative NAID has 
been associated with poor outcomes (increased rates 
of post-operative infections, transfusion, fatigue)49,50. 
Although it is presently unknown whether pre-operative 
correction of NAID may offset the excess of risk of 
post-operative complications, guidelines recommend 
peri-operative iron supplementation for patients with 
NAID16,17. 
Beyond iron therapy, interventions to find the 
source of blood or iron loss (e.g., gastro-intestinal 
investigation) are also necessary in these individuals, 
especially men and non-menstruating women with 
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new-onset, absolute ID (ferritin <30 ng/mL)3,17. Patients 
with microcytosis due to NAID should be evaluated 
for chronic hypoxaemia, myeloproliferative disease 
(e.g. polycythaemia rubra vera), or another cause of 
increased red cell production (increased iron use). Iron 
replacement may cause a surge in haemoglobin that 
could induce hyperviscosity in this subgroup6. 
In a healthy adult, 1 ng/mL of serum ferritin reflects 
approximately 8 mg of stored iron, whereas 200-250 mg 
of iron is required to raise the haemoglobin concentration 
by 1 g/dL51. In patients experiencing peri-operative 
blood loss leading to a haemoglobin drop ≥3 g/dL, a pre-
operative ferritin <100 ng/mL may reflect inadequate 
(low) iron stores to sustain erythropoiesis for recovering 
their basal haemoglobin levels and maintain normal iron 
stores (ferritin ≥30 ng/mL)16,17,52. 
In major orthopaedic surgery, the pre-operative 
administration of ferrous sulphate and vitamins (B12 and 
folate) increased serum ferritin and transferrin saturation 
and reduced transfusion rate53,54. However, adherence 
to iron supplementation was 67%, and adverse drug 
reactions were present in 52% of patients55. IV iron 
administration (e.g., 500 mg) should be considered if 
there is <4 weeks until surgery or the patient cannot 
tolerate oral iron6,7,56. In orthopaedic and cardiac surgery, 
peri-operative IV iron may reduce transfusion rates; 
it preserves iron stores and hastens the recovery from 
post-operative anaemia57-60. 
Key points
- Iron stores should be replaced with oral or intravenous 
iron in most patients with non-anaemic iron 
deficiency to improve symptoms and/or avoid the 
development of iron-deficiency anaemia. 
- Patients with low iron stores (ferritin < 100 ng/mL) 
undergoing surgery with a high risk of developing 
severe post-operative anaemia may benefit from 
peri-operative oral or IV iron supplementation.
- It is imperative to find the source of decreased 
iron, such as reduced uptake, increased iron loss, or 
increased iron use, in both iron-deficiency anaemia 
and non-anaemic iron deficiency. Patients should be 
proactively treated while these searches are ongoing.
Misconception #3 
Oral iron is "always" efficacious if patients tolerate 
high daily doses
The mainstay therapy for ID is oral iron which 
is effective, readily available, safe, and inexpensive 
(especially for low-resource countries). Oral iron avoids 
the need for venous access and infusion monitoring, and 
eliminates the risk of infusion reactions. It is, however, 
time-consuming and requires months of treatment to 
correct anaemia and replenish iron stores.
There is a huge variety of formulations of ferrous 
salts (sulphate, gluconate, fumarate, etc.) and ferric 
complexes (amino acids, polysaccharide, ovo-albumin, 
etc.) which are available as tablets, elixirs or solutions. 
There is no evidence that one iron salt formulation is 
more effective or has fewer side effects than another, 
as long as they are taken61. However, as they are poorly 
absorbed, the use enteric-coated formulations should 
be avoided62. Data from randomised controlled trials 
indicate that non-salt-based oral iron formulations, 
such as ferrous bis-glycinate chelate, ferric maltol or 
sucrosomial iron, may represent an alternative option 
for patients with intolerance of iron salts or those on 
maintenance therapy with IV iron, though more studies 
are needed63-67.
Oral iron is usually prescribed at a high dose (100-
200 mg elemental iron) to be taken one to three times 
a day. Up to 70% of patients on oral iron (especially 
ferrous sulphate) report gastrointestinal side effects, due 
to exposure to unabsorbed iron, which ultimately reduces 
tolerance and adherence to treatment68. 
However, lower-dosage iron supplements can be 
effective for treating ID and are associated with fewer 
gastrointestinal side effects. In non-anaemic young 
women with plasma ferritin levels <20 ng/mL, providing 
lower dosages (40-60 mg elemental iron) and avoiding 
twice-daily dosing was found to maximise fractional 
absorption due to the reduced effect of absorbed iron 
on hepcidin release69. 
Whether these data also apply to IDA is not known. 
Anaemia-induced hypoxia and erythropoietin production 
down-regulate hepcidin expression70, and this may 
counterbalance the stimulatory effect of iron, allowing 
the use of higher oral iron doses. In a randomised study, 
90 patients with IDA (average age 85 years) received 
15 mg, 50 mg or 150 mg of elemental iron per day. At 
two months, there were no between-group differences 
in the levels of haemoglobin or ferritin. Haemoglobin 
increased 1.4 g/dL in the three groups, but adverse effects 
were significantly more common with higher doses71. 
In an observational study of patients with inflammatory 
bowel disease with mild-to-moderate anaemia, oral iron 
treatment (100 mg/day) was effective and well tolerated 
by most patients, did not exacerbate the symptoms of 
the underlying inflammatory bowel disease, and was 
associated with a relative improvement in quality of 
life72. Based on these findings a new paradigm for low-
dose, alternate-day iron may be prudent.
There are a number of commonly used medications 
(tetracycline, antacids, proton pump inhibitors, H2 
antagonists, etc.) which reduce the absorption of iron 
salts. It is recommended that oral iron be taken 12 hours 
apart from these drugs. The intake of iron salts together 
with food also reduces absorption of iron, but increases 
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the tolerance. Should the patient develop intolerance of 
iron salts, switching to another oral iron formulation or 
to IV iron may be appropriate3,62.
Key points
- Patients with mild-to-moderate iron-deficiency 
anaemia may benefit from oral iron therapy provided 
that there is tolerance of and no contraindications to 
oral iron.
- Low daily doses (e.g., 50 mg) or moderate doses 
(e.g., 100 mg) every other day may increase both 
tolerance and efficacy of oral iron supplementation.
- Once anaemia is corrected, oral iron supplementation 
should be continued for at least 3 months to replenish 
iron stores.
Misconception #4
The use of intravenous iron should be restricted to 
severe cases of anaemia
Severe IDA presenting with alarming symptoms, 
such as haemodynamic instability, or risk criteria, 
such as coronary heart disease, should be treated with 
red blood cell transfusion using the minimal amount 
necessary to achieve clinical stability. Adhering to 
patient-adapted restrictive transfusion criteria and 
transfusing one unit at the time, with post-transfusion 
reassessment, is strongly recommended by the majority 
of guidelines22,73-75.
Red blood cell transfusion produces a rapid, albeit 
transient, rise in haemoglobin, increasing oxygen-
carrying capacity. However, severe IDA will recur 
unless the cause is identified and addressed, if possible. 
After haemodynamic stability has been achieved with 
transfusion, additional iron supplementation should be 
considered with the IV route preferred.
IV iron has been demonstrated to be superior to oral 
iron in a number of clinical settings76-81. Furthermore, 
IV iron is a necessity when oral iron cannot be 
taken or is ineffective, such as in the presence of 
inflammation or on-going blood loss. Its avoidance 
is not only counterproductive but potentially harmful, 
and limiting its use will dramatically increase ESA 
usage as well as red blood cell transfusions with their 
associated complications82. Unlike ESA, IV iron does 
not increase haemoglobin concentrations beyond 
recommended levels, but it has been reported to reduce 
ID-induced secondary thrombocytosis, which may 
contribute to lowering the risk of thromboembolic 
complications41,45-47,83. The use of IV iron formulations 
which allow infusion of high doses of iron (1,000 mg 
or more), such as low molecular weight iron dextran 
(LMW ID), FCM, or iron isomaltoside-1000 (ISM), in 
a short time (15-60 minutes), offers added convenience 
to both physicians and patients84,85.
Key points
- For patients with severe iron-deficiency anaemia, 
administration of intravenous iron is the replacement 
therapy of choice.
- In the settings of intolerance of, or refractoriness to 
oral iron, active bleeding, inflammatory conditions, 
erythropoiesis-stimulating agent treatment, or need 
for a rapid recovery of haemoglobin, switching to 
intravenous iron therapy is appropriate for managing 
mild-to-moderate anaemia. 
- The use of intravenous iron formulations that allow 
nearly full iron replacement in one or two infusions 
is preferred for most patients.
- When offering intravenous iron therapy to people 
not receiving haemodialysis, consider high-dose, 
low frequency intravenous iron as the treatment of 
choice for adults and young people when trying to 
achieve iron repletion.
Misconception #5
There is no need for re-assessment after iron repletion 
with intravenous iron
A full response to IV iron administration can take up 
to six-eight weeks. Patients experience an improvement 
of well-being within a few days, the reticulocyte count 
rises in one week, and haemoglobin increments are 
seen in one or two weeks. Depending on the severity of 
anaemia, normal levels will be reached in most patients 
in one or two months. Therefore, after initial IV iron 
repletion and depending on underlying co-morbidities, a 
reassessment of both response and iron status is prudent 
as further iron supplementation is often required (oral 
or IV)15,62,86. 
Generally, reassessment should be performed no 
earlier than four-six weeks after treatment to allow 
adequate time for erythropoiesis and iron utilisation, 
and to avoid interference of IV iron with assays of iron 
status (standard laboratory methods do not discriminate 
between transferrin-bound iron, compound-bound iron 
and labile iron)62.
When there is chronic ongoing blood loss 
or participation in a pre-operative haemoglobin 
optimisation programme more frequents visits may 
be required to evaluate the response and establish 
an effective iron dose. Recently Theusinger et al.87 
reported on the results of a pragmatic approach 
to pre-operative anaemia management in major 
orthopaedic surgery (2009-2011; n=6,721). If there 
were no contraindications, patients presenting with 
a haemoglobin <13 g/dL received 1,000 mg IV iron 
and 40,000 IU recombinant human erythropoietin 
(rHuEPO) subcutaneously, and were reassessed two 
weeks later. Those whose haemoglobin remained <13 
g/dL received a second dose of IV iron and rHuEPO. 
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All treated patients presented with normal haemoglobin 
levels (≥13 g/dL) on the day of surgery. 
If haemoglobin and iron status do not normalize, the 
cause for this failure should be carefully determined62,88. 
Patients at risk of recurrent ID, such as those with 
cancer, CKD, chronic heart failure, inflammatory bowel 
disease, history of gastric bypass, heavy menstrual 
bleeding, hereditary haemorrhagic telangiectasia, 
malabsorption, or any condition in which active blood 
loss exceeds absorptive capacity, should be assessed at 
frequent intervals to determine whether maintenance 
iron supplementation is indicated15,62,86,89-92.
Key points
- The haematological response to intravenous iron 
should be assessed, and the need for further iron 
supplementation established, six to eight weeks after 
initial iron repletion.
- Lack of response to intravenous iron should be 
appropriately investigated.
- Patients responding to initial intravenous iron therapy 
but at risk of the iron deficiency recurring should be 
periodically reassessed and/or receive maintenance 
oral or intravenous iron supplementation.
Misconception #6
All intravenous iron formulations are alike
Currently, six IV iron formulations are available for 
clinical use worldwide: ferric gluconate (FG), iron sucrose 
(IS), low molecular weight iron dextran (LMWID), 
ferric carboxymaltose (FCM), iron isomaltoside-1000 
(ISM), and ferumoxytol (FXT) (Table I). 
For the approved indications and at recommended 
doses, all the available IV iron formulations are 
essentially equal in terms of safety and efficacy82,93. 
This statement only applies to original IV iron 
formulations. In dialysis-dependent (DD)-CKD patients, 
the switch from the originator IS to an IS similar led 
to higher iron and ESA doses required and incurred 
and increased total anaemia treatment costs; this 
situation reverted after a switch back to the originator 
IS94,95. The European Medicines Agency states that 
current scientific knowledge and regulatory experience 
for characterisation of nano-sized colloidal IV iron 
preparations indicate that quality characterisation, on 
its own, would not provide sufficient assurance of 
the similarity between the two products, even if the 
quality tests performed show similarity. In the context 
of such iron-based preparations, a "weight of evidence 


















Molecular weight (kDa) 289-440 30-60 165 150 150 750
Labile iron (% injected dose)1 3.3 3.5 2.0 0.6 1.0 0.8
Maximal single dose (mg) 125 200 20 mg/kg 20 mg/kg 
(max 1,000 mg) 
20 mg/kg 510
Infusion time for 1,000 mg (min)2 720 300 180* 45 45 90
Product cost per 1,000 mg (€)3 - 112 103 192 192 1624
Administration cost per 1,000 mg (€)5 554 231 139 35 35 70
Total cost per 1,000 mg dose (€) - 342 242 227 227 232
1) Jahn MR, et al. Eur J Pharm Biopharm 2011; 78: 480-91.
2) Includes 30 min post-infusion observation.
3) Quintana-Díaz M, et al . Blood Transfus 2017; 15: 438-46.
4) British National Formulary BNF68, September 2014 - March 2015. BMJ Group and the Royal Pharmaceutical Society of Great Britain, 
London, 2014.
5) Includes infusion time cost and post-infusion time (30 min) cost at day-hospital (€ 277/6 hours; € 0.77/min), according to official prices 
for healthcare services in the Autonomous Community of Madrid (Spain). 
6) Ferrlecit summary of product characteristics. Available at: http://www.products.sanofi-aventis.us/ferrlecit/ferrlecit.pdf; Accessed on 
18/01/2017.
7) Venofer summary of product characteristics. Available at: http://www.luitpold.com/documents/22.pdf. Accessed on 18/01/2017.
8) LMWID, low molecular weight iron dextran; Cosmofer summary of product characteristics. Available at:http://www.cosmofer.com/
product/cosmofer-spc/cosmofer-spc.aspx. Accessed on 18/01/2017.
9) Ferinject summary of product characteristics. Available at: http://www.ferinject.co.uk/smpc/. Accessed on 18/01/2017.
10) Monofer summary of product characteristics. Available at: http://www.monofer.com/spc.aspx; Accessed on 18/01/2017.
11) FeraHeme summary of product characteristics. Available at: http://www.feraheme.com/pdfs/Feraheme_Prescribing_Information.pdf. 
Accessed on 18/01/2017.
* Although it is not an approved dosing by the USA Food and Drug Administration or European Medicines Agency, Auerbach et al. (Am 
J Hematol 2011; 86: 860) did not observed any serious adverse events in over 5,000 administration of LMWID at doses of 1,000 mg in 
250 mL of normal saline over 1 hour (estimated total cost per 1,000 mg dose in Spain € 173).
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approach" including data from quality, non-clinical 
and human pharmacokinetic studies is required96. 
There are remarkable differences in originator 
compound structures which may greatly influence 
feasibility and cost of treatment courses (acquisition 
cost, number of doses, and infusion time)97,98. FCM is 
the IV iron formulation for which there is the highest 
level of clinical evidence, and is currently the only 
one recommended in the European guidelines for the 
management of ID in heart failure19. However, there is 
no published evidence suggesting a clinical advantage 
of one formulation over another.
Acquisition costs for different IV iron formulations 
could be subject to purchasing agreements among 
hospitals, health-care providers, distributors and 
manufacturers. Thus, they may vary widely between 
and within countries. As shown in Table I, in Spain, 
the acquisition costs of LMWID, FCM and ISM are 
considerably higher than that of IS (FG and FXT are not 
available). As iron is strongly bound to carbohydrates in 
these IV formulations, the amount of labile iron available 
is very low, thus allowing rapid administration of large 
single doses. Current evidence does not support a benefit 
for therapeutic doses exceeding 1,000 to 1,500 mg3,62. 
All this facilitates full iron replacement, with fewer visits 
necessary, resulting in reduced administration costs. 
These advantages may outweigh the higher acquisition 
costs of such iron formulations, and result in significantly 
lower total costs99-103. Estimated total costs for FXT are 
similar to those for LMWID, FCM and ISM, whereas 
those for FG and IS are significantly higher (Table I). In 
the USA, centres are paid $ 68 for an hour in the chair 
for IV iron and $ 41 for 15 minutes. Acquisition costs for 
1,000 mg IV iron are significantly higher in the United 
States of America than in Europe.
The European Medicines Agency recommends close 
monitoring for signs of hypersensitivity during and for 
at least 30 minutes after every administration of an IV 
iron product104. The guidelines for risk minimisation and 
management of hypersensitivity reactions to IV iron also 
suggest observation/monitoring every 15 minutes during 
the infusion and for 30 minutes after its completion, 
especially for patients at risk such as those who have 
had a previous adverse reaction to IV iron or have 
more than one drug allergy, a history of severe atopy, 
pre-existing severe respiratory or cardiac disease, or are 
taking beta-blockers or angiotensin-converting enzyme 
inhibitors105. In contrast, since IV iron delivery should 
not be associated with a severe delayed reaction, the 
KDIGO Controversies Conference considered that there 
is no physiological basis to recommend that patients 
should be observed for 30 minutes after an infusion of 
IV iron has been completed106. 
With regards to dose, data from some trials 
comparing IV iron administration at "lower dose" (IS) 
with "higher dose" (FCM, ISM, FXT)107-110 showed 
a higher proportion of patients with a haemoglobin 
increase ≥2 g/dL from baseline at any time of the study 
and/or a shorter time to get such an increase with higher 
dose IV iron. Biochemical iron parameters improved 
both faster and quantitatively more with higher dose IV 
iron, compared to lower dose107-113. 
Key points
- There are structural differences between intravenous 
compounds which greatly influence feasibility and 
cost of treatment courses.
- Intravenous iron formulations allowing higher 
dose administration are more convenient both for 
the patient (fewer venous punctures, less time off 
work, etc.) and the healthcare system (fewer visits to 
day hospital, less ambulance transport, etc.). These 
advantages outweigh higher acquisition costs, and 
result in significantly lower total costs of treatment.
Misconception #7
Intravenous iron is associated with a high risk of 
anaphylaxis
A report from the European Medicines Agency's 
Committee for Medicinal Products for Human Use 
(CHMP) stated that all IV iron medicines are associated 
with a small risk of causing allergic reactions which can be 
life-threatening if not treated promptly, but the benefits of 
IV iron exceed its risks provided that adequate measures 
are taken to minimise such reactions. The CHMP report 
also added that "data on the risk of hypersensitivity 
comes mainly from post-marketing spontaneous 
reports and the total number of life-threatening and 
fatal events reported is low" and "although the data 
show a clear association of intravenous iron medicines 
and hypersensitivity reactions, the data cannot be used 
to detect any differences in the safety profile of the 
different iron medicines"104. High-molecular weight 
iron dextran, which produced hypersensitivity reactions 
more frequently than any other IV iron formulation, 
is no longer available, and was not addressed in this 
manuscript. Overall, the currently available formulations 
are much safer, with estimated serious adverse events 
rates of <1:250,000 administrations. 
These conclusions were recently called in question by 
a publication from the Food and Drug Administration in 
the USA. Wang et al.114 retrospectively reviewed a large 
cohort of new users of IV iron (n=688,183), enrolled in 
the United States of America fee-for-service Medicare 
programme from January 2003 to December 2013, to 
compare the risk of anaphylaxis among marketed IV 
iron products. The overall incidence was low, but a 
higher risk of anaphylaxis was found for iron dextran 
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compounds when compared to non-iron dextran (FG, IS, 
and FXT) (68/100,000 vs 24/100,000; p<0.001). 
However, this could be an overestimation as high-
molecular weight iron dextran was included, which is 
known to be associated with a higher risk of adverse 
reactions and was still available during the conduct of 
the study. Only Medicare patients were involved (with 
a mean age >70 years), so the majority of subjects who 
receive IV iron were not studied. These include patients 
with heavy uterine bleeding, pregnancy, after bariatric 
surgery and inflammatory bowel disease. Consequently, 
the population studied was not representative of patients 
receiving IV iron115. There are no data available for 
FCM or ISM in the USA. A recent evaluation suggests 
that adverse reactions are less common with newer 
formulations93.
Similarly, although the USA Food and Drug 
Administration's Adverse Event Reporting System 
database is a valuable resource for reporting suspected 
allergic/anaphylactic reactions, it does not allow 
conclusions to be drawn about absolute risks and/or 
relative risks among IV iron products116. 
Subtracting the risk of anaphylaxis from the combined 
risk of anaphylaxis or death, enabled the risk of death 
to be estimated (see Wang et al., 2015, supplementary 
files)114. Interestingly, the risk of death on the date of first 
administration for incident IV iron users was an order of 
magnitude lower for iron dextran (0.8/100,000) than for 
IS (6.1/100,000), FG (6.4/100,000) or FXT (3.7/100,000). 
These data effectively contradict their conclusions. 
We deem that the risk profile of IV iron therapy 
should also be compared to the risk of death and serious 
adverse events resulting from transfusion therapy. 
In fact, although haemovigilance and progress are 
improving the safety of transfusions with regards to 
infectious risks, the risks of death and non-infectious 
SAE (as estimated from Serious Hazards Of Transfusion 
[SHOT] data in 2012) are one in 322,580 and one in 
21,413 components issued, respectively117.
An incompletely understood side effect is fibroblast 
growth factor-23-induced hypophosphataemia which 
seems to affect patients receiving some IV iron 
preparations more than others (especially with FCM). 
IV iron induces an increase of biologically active, 
intact fibroblast-growth factor 23 that reduces renal 
phosphate absorption, leading to hypophosphatemia 
which may persist for up to six months. Generally, 
hypophosphataemia is of no clinical significance, 
although it may present with symptoms which are similar 
to those produced by anaemia, and there are case reports 
of patients requiring enteral and parenteral replacement 
therapy for some time after administration118-121. 
However, phosphate levels do not need to be checked 
routinely unless significant malnutrition is present3,62.
In conclusion, although we believe that IV iron rarely 
causes serious adverse effects, it would be imprudent to 
ignore the history of reported life-threatening events. 
A recent excellent monograph on the management of 
hypersensitivity reactions to IV iron105 supports our 
conclusions but cautions physicians to have immediately 
available the necessary therapeutic modalities to handle 
life-threatening hypersensitivity reactions. These authors 
also developed an excellent algorithm which provides 
intelligent recommendations to avoid unnecessary 
interventions while guiding clinicians on how to handle 
the extremely rare but serious events. The proposed 
algorithm is similar to that in the KDIGO Controversies 
document106. In this algorithm, anti-histamines have no 
role as pre-medication or part of the treatment paradigm.
Key points
- All intravenous iron formulations are essentially 
equally safe and efficacious.
- All intravenous iron medicines carry a very low 
risk of causing allergic reactions which can be 
life-threatening if not treated promptly.
- Physicians should have immediately available 
the necessary therapeutic modalities to handle 
life-threatening hypersensitivity reactions and 
follow a well-designed algorithm.
Misconception #8
Premedication reduces infusion reactions during 
intravenous iron administration
Many clinicians are still reluctant to use IV iron 
due to concerns about anaphylaxis, although true 
life-threatening allergic reactions are exceedingly 
rare and vastly overestimated93,106. Early formulations 
of high molecular weight iron dextran were associated 
with occurrences of anaphylaxis and even death, whereas 
newer formulations are much safer with severe adverse 
events vanishingly rare. Nonetheless, minor infusion 
reactions still occur and are often misinterpreted as 
serious adverse events122. 
Premedication with antihistamines (diphenhydramine) 
was reported to have caused the majority of perceived 
reactions to IV iron in one large cohort123. Antihistamines 
can cause somnolence, diaphoresis, hypotension and 
tachycardia which can be erroneously attributed to 
the administered iron. Tryptase levels, a marker of 
mast cell degranulation, are virtually always normal 
and consequently the use of premedication with 
antihistamines should not be advised124.
All iron formulations can be associated with acute 
chest and back tightness, without accompanying 
hypotension, tachypnoea, tachycardia, wheezing, 
stridor or periorbital oedema106,125,126. Although the 
cause has not been clearly elucidated, these reactions 
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are consistent with minor reactions to labile free iron106. 
A novel postulate as a potential aetiology is activation 
of the complement system (the so-called, complement 
activation-related pseudo allergic, CARPA), and may 
be more serious105. 
Normally, reactions to "free" or "labile" iron abate 
spontaneously without any therapy and rarely recur with 
re-challenge. If symptoms recur, switching to another IV 
formulation is appropriate. Thus, aggressively treating 
non-allergic infusion reactions with diphenhydramine 
or vasopressors should be avoided as it may convert this 
mild reaction into a more serious adverse event. It is also 
important to be mindful that these infusion reactions should 
not be misinterpreted as hypersensitivity, as the European 
Medicines Agency stated that "intravenous iron containing 
products must also not be used in patients with serious 
hypersensitivity to other parenteral iron products" 104.
The reactions are more frequent in those with allergic 
diatheses82. Patients with asthma or more than one drug 
allergy, who are at slightly increased risk of an allergic 
or infusion reaction, may benefit from pre-medication 
with steroids or H2 blockers prior to administration of 
IV iron127. For those with inflammatory arthritis a short 
course of prednisone (1 mg/kg/day orally for 4 days) 
may prevent a flare128,129.
A few patients will experience self-limited arthralgia 
and myalgia the day after iron infusions. These 
reactions abate without therapy, leaving no sequelae, 
but administration of non-steroidal anti-inflammatory 
medications may shorten their duration62. 
When these recommendations are borne in mind, 
the administration of IV iron is a safe procedure, being 
much safer than most physicians realise.
Key points
- Premedication with antihistamines does not prevent 
infusion reactions and should be proscribed.
- Aggressive management of non-allergic infusion 
reactions with diphenhydramine and other therapies 
may convert a mild reaction into a more serious 
adverse event.
- Patients with asthma or drug allergies should be 
routinely pre-medicated with methylprednisolone 
or hydrocortisone prior to intravenous iron 
infusion.
- Non-steroid anti-inflammatory drugs may be useful 
for treating post-infusion arthralgia or myalgia if 
there are no contraindications
Misconception # 9 
Intravenous iron may increase the risks of infection 
and oxidative stress
Current information on the relationship between IV 
iron and infection, and between IV iron and oxidative 
stress, deserves special consideration. However, we should 
differentiate between short-term IV iron administration 
(usually given as one or two large doses) and long-term 
IV iron therapy (as is the case for patients with CKD).
Elemental iron is an essential growth factor for 
bacteria, with many species expressing iron transport 
proteins that compete with transferrin, and it has long 
been suggested that patients with iron overload are at 
increased risk of infection130. In a systematic review and 
meta-analysis evaluating the efficacy and safety of IV 
iron, Litton et al.131 reported that IV iron resulted in a 
significant increase in mean haemoglobin concentration 
(6.5 g/L; 95% CI [confidence interval]: 5.1-7.9 g/L), a 
reduction of transfusion risk (relative risk 0.74; 95% CI: 
0.62-0.88), and no significant difference in mortality or 
serious adverse events compared with oral iron or no 
iron supplementation, but IV iron was associated with 
a significant increase in risk of infection of 1.33 (95% 
CI: 1.10-1.64). However, the conclusions of this meta-
analysis are undermined by study limitations (search 
strategy was incomplete, infection was not a predefined 
endpoint in many studies, a dose-response relationship 
was not found), and are somewhat contradictory to most 
other published studies132.
A more recent meta-analysis of 103 trials published 
between 1965 and 2013 (including 19,253 treated 
patients: 10,390 with IV iron, 4,044 with oral iron, 
1,329 with no iron, 3,335 with placebo, and 155 with 
intramuscular iron) concluded that IV iron therapy 
was not associated with an increased risk of serious 
adverse events (relative risk: 1.04; 95% CI: 0.93-1.17) 
or infection (relative risk: 0.96; 95% CI: 0.63-1.46), 
when compared with oral or intramuscular iron, no 
iron or placebo79. In large observational studies, peri-
operative IV iron reduced transfusion rates and did 
not have negative effect on rates of infection and 30-
day mortality in surgical patients. In contrast, red cell 
transfusions deliver haem and labile iron, which support 
bacterial growth more readily135. Despite the absence 
of definitive clinical data, it seems sensible to avoid IV 
iron administration in the setting of acute infection52.
Regarding patients on long-term IV iron therapy, one 
study of 117,050 DD-CKD patients reported that bolus 
dosing, when compared to maintenance dosing, was 
associated with a higher risk of infection-related hospital 
admissions, as well as infection-related mortality. 
However, maintenance or low-dose iron dosing was 
not associated with a higher risk of infection-related 
hospitalisation or mortality outcomes when compared 
with no iron136. Similarly, a small single-centre trial in 
non-dialysed CKD patients, showed a higher rate of 
cardiovascular events and infections requiring hospital 
admission in the group receiving IV iron137. In contrast, 
in the largest and longest trial (FIND-CKD, n=626) 
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ever conducted evaluating IV vs oral iron in anaemic, 
non-dialysed CKD patients with ID and not receiving 
ESA therapy, MacDougall et al.138 did not find any 
difference in infection rates between patients receiving 
higher dose FCM (500-1,000 mg/4 weeks), lower dose 
FCM (200 mg/4 weeks) or oral ferrous sulphate (200 
mg/day) during the 56-week follow-up (3.9%, 3.3%, 
and 3.8%, respectively).
A recent meta-analysis of 24 trials on IV vs oral iron 
supplementation in CKD patients (13 trials including 
2,369 patients with CKD stages 3 to 5 and 11 including 
818 patients with CKD stage 5D) showed similar rates of 
mortality, serious adverse events and any adverse events. 
Nevertheless, IV iron replacement was associated with 
a higher risk of hypotension (relative risk: 3.71; 95% 
CI: 1.74-7.94) and fewer gastrointestinal adverse events 
(relative risk: 0.43; 95% CI: 0.28-0.67)139.
The available evidence relating IV iron administration 
to oxidative stress leading to atherogenesis and vascular 
remodelling is indirect, and there is little to no evidence 
that IV iron adversely affects survival in patients with 
DD-CKD, as most data come from observational, 
retrospective studies. In a cohort of 58,058 DD-CKD 
patients, IV iron doses greater than 400 mg/month were 
associated with higher cardiovascular death rates140, 
whereas a larger retrospective study on DD-CKD 
patients showed no association between large doses 
of iron and short-term cardiovascular morbidity and 
mortality141. In the FIND-CKD study the incidences 
of cardiac events were identical across all three groups 
(high-dose FCM, low-dose FCM, and oral iron)138. In 
patients with congestive heart failure, who may also 
present with CKD, ID was independently associated 
with cardiovascular mortality, while IV iron therapy 
improved functional status20.
The conclusion should be that "too much iron is 
bad" for CKD patients, but further large clinical studies 
are needed. The on-going Proactive IV irOn Therapy 
in haemodiALysis (PIVOTAL) (EudraCT Number: 
2013-002267-25) trial is a four-year trial and will 
involve over 2,000 patients from 50 renal units in the 
UK. This is the largest renal clinical trial ever undertaken 
comparing a high-dose vs a low-dose IV iron regimen. 
Hard end-points include the risk of death, myocardial 
infarction, stroke, heart failure, and infections. Changes 
in laboratory parameters, quality-of-life and ESA 
requirements will also be monitored. It is hoped that the 
PIVOTAL results will fill many gaps in our knowledge 
on IV iron therapy in CKD patients142.
Key points
- Data from meta-analyses and large observational 
studies indicated that short-term intravenous iron 
therapy was not associated with an increased risk of 
infection when compared to oral iron or no iron.
- In dialysis-dependent patients with chronic kidney 
disease on long-term intravenous iron maintenance 
therapy, low-dose iron dosing was not associated with 
a higher risk of infection-related hospital admissions 
or mortality outcomes when compared with no iron. 
- In non dialysis-dependent patients with chronic 
kidney disease on long-term intravenous iron 
maintenance therapy, neither lower nor higher iron 
dosing seems to be associated with a higher risk of 
infection when compared with oral iron.
- There is no convincing evidence that intravenous iron 
administration induces significant oxidative stress 
leading to cardiovascular morbidity and mortality.
Misconception #10
No adjuvant iron is needed with erythropoiesis-
stimulating agent treatment if the ferritin level is 
normal 
ESA increase erythropoiesis in a dose-dependent 
fashion, although their stimulatory effect may be 
reduced by inflammation143. Iron does not directly 
stimulate erythropoiesis, but an adequate supply to 
the bone marrow is indispensable for building up 
haemoglobin. Inflammation-induced hepcidin synthesis 
leads to sequestration of iron, thus decreasing iron 
mobilisation from stores. ESA increase intestinal iron 
absorption, and decrease hepcidin synthesis (through the 
stimulation of erythroferrone release by erythroblasts) 
facilitating iron mobilisation. Functional ID refers to 
insufficient mobilisation of iron from stores to meet 
the increased demands imposed by high-dose ESA, 
even in the presence of normal iron stores. Importantly, 
insufficient iron supply during ESA treatment leads to 
thrombocytosis1,7,47.
Administration of ESA is indicated for iron-
replete patients who are anaemic due to CKD or 
chemotherapy18,22,106. ESA are also used to optimise 
pre-operative haemoglobin levels in patients scheduled 
for major surgery in which moderate-to-high blood loss 
is expected. Assessment of iron status and correction 
of ID are mandatory before starting ESA therapy144,145. 
In the presence of functional ID, adjuvant iron therapy 
improves the haemoglobin response to ESA73,146,147.
A systematic Cochrane review of studies of cancer 
and chemotherapy-associated anaemia, including eight 
randomised controlled trials comparing ESA plus iron 
vs ESAs alone in 2,087 participants (12 comparisons), 
showed that addition of IV iron to ESA produces a 
faster and superior haematopoietic response, reduces 
the risk of red blood cell transfusions, improves 
haemoglobin levels, and appears to be well tolerated, in 
comparison with oral iron salts or no iron148. In addition, 
a randomised controlled trial of 67 anaemic onco-
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haematological patients not receiving chemotherapy 
(40% functional ID), and supported with rHuEPO 
beta and oral iron or IV iron sucrose, showed that 
rHuEPO plus IV iron resulted in an 11% overall cost 
savings compared to ESA without iron supplementation 
(€ 2,178/patient/year). This reduction in overall cost was 
largely driven by reduced rHuEPO dosages (saving of 
€ 3,829/patient/year), irrespective of the cost incurred 
for IV iron supplementation (€ 1,654/patient/year)149,150.
It is recommended that iron supplementation is 
started immediately in all iron-deficient cancer patients 
prior to them receiving an ESA. For those hypo-
responsive to ESA with functional ID, the addition of 
IV, and not oral iron, is recommended. Whereas there are 
no guidelines on dosing, the new European Society for 
Medical Oncology/European Organisation for Research 
and Treatment of Cancer (ESMO/EORTC) guidelines 
recommend 1,000 mg IV iron to be given together with the 
initiation of ESA151. However, a small trial found similar 
efficacy but better tolerance of oral sucrosomial iron 
(30 mg/day) compared to IV iron (FG, 125 mg/week) 
in 64 anaemic cancer patients without absolute or 
functional ID, scheduled to receive chemotherapy and 
darbepoetin alfa for eight weeks66. Thus, newer oral 
iron formulations may prevent functional ID in some 
subgroups of patients, such as those with cancer or 
CKD152,153, although further studies are warranted. 
It must be borne in mind that the joint guideline 
from the American Society of Clinical Oncology and 
the American Society of Hematology (ASCO-ASH) 
recommend using ESA therapy with great caution in 
patients with active malignancy, particularly when 
cure is the anticipated outcome154. The Medicines and 
Healthcare Products Regulatory Agency (MHRA) 
advised that ESA should not be given to patients with 
cancer who do not fulfil the criteria in the authorised 
cancer indications, and that patients should be monitored 
closely to ensure that the lowest approved dose of ESA 
is used to adequately control of symptoms of anaemia155.
In the TREAT study on CKD patients with diabetes, 
there was an increased risk of stroke in the high-dose 
ESA group (hazard ratio: 1.92; 95% CI: 1.38-2.68) and 
venous thrombo-embolic events occurred significantly 
more frequently in the high haemoglobin arm (2.0%) 
compared to the placebo arm (1.1%, p=0.02)156. A 
meta-analysis of ESA use in CKD found that targeting 
higher haemoglobin levels in CKD increases risks of 
stroke, hypertension, and vascular access thrombosis and 
probably increases risks of death, serious cardiovascular 
events, and end-stage renal disease157. Relative 
thrombocytosis induced by ESA in the presence of 
functional ID was a possible explanation for the 
increased thrombotic risk158. 
In CKD patients, adjuvant IV iron has long been 
recognised to improve haematological response and to 
reduce the dose of ESA required (KDIGO). Additionally, 
in the FIND-CKD trial, IV FCM targeting a ferritin 
of 400-600 ng/mL quickly reached and maintained 
haemoglobin level, and delayed and/or reduced the 
need for other anaemia management including ESA138. 
In the setting of orthopaedic surgery, a large 
randomised controlled trial demonstrated that the 
administration of four doses of an ESA (rHuEPO 
40,000 IU plus oral iron, starting three weeks prior to 
the scheduled procedure) decreased transfusion rates in 
patients undergoing lower limb arthroplasty or spinal 
surgery159. In contrast, in a more recent study with a 
similar design, rHuEPO was found to significantly 
reduce the number of patients requiring allogeneic 
blood transfusion but not the number of allogeneic 
units transfused, at unacceptably high costs (€ 7,300 
per avoided transfusion)160, calling into question the 
routine use of four doses of rHuEPO. Data from several 
studies suggest that one or two doses of rHuEPO 
could be sufficient to reach a target haemoglobin 
level ≥13 g/dL, especially when co-adjuvant IV iron 
is administered87,161,162. These results suggest a possible 
role for iron supplementation as monotherapy. Three 
small trials have shown that administration of iron 
without ESA in women receiving chemotherapy 
prevented a haemoglobin fall during treatment cycles 
and led to a significant reduction of transfusion 
requirements163-165. A large observational study in 
anaemic cancer patients receiving iron indicated that 
patients with baseline haemoglobin levels up to 11.0 
g/dL and a serum ferritin level ≤500 ng/mL had an 
increase in haemoglobin and a reduction in the need 
for blood transfusions166. Additionally, in patients 
with gastrointestinal cancer (mostly colorectal cancer) 
scheduled for potentially curative surgery, pre-operative 
administration of IV iron improved haemoglobin levels 
and reduced transfusion requirements and/or time spent 
in hospital167-170. Therefore, iron supplementation as 
monotherapy is recommended for ID cancer patients 
who cannot receive ESA73.
Key points
- Assessment of iron status and correction of 
iron deficiency are mandatory before starting 
erythropoietin-stimulating agent therapy.
- Functional iron deficiency should be corrected with 
intravenous iron.
- Addition of intravenous iron to erythropoiesis-
stimulating agents leads to a faster and superior 
hematopoietic response, reduces the risk of red 
blood cell transfusions, is well tolerated, and reduces 
overall treatment costs when compared to oral iron 
salts or no iron.
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- In chronic kidney disease and cancer-associated 
anaemia, monotherapy with intravenous iron may 
result in increased haemoglobin, reduced needs for 
blood transfusions, and delayed and/or reduced needs 
for erythropoiesis-stimulating agents, the latter of 
which may increase the risk of cancer recurrence.
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